The earnings call highlighted strong revenue growth and product expansions, including a significant increase in core revenue and successful market expansions. However, increased operating expenses and sustained losses, alongside anticipated seasonal slowdowns, present challenges. Overall, the positive aspects slightly outweigh the negatives.

Company Guidance -

Q3 2025

During the Fulgent Genetics Q2 2025 Conference Call, the company provided updated guidance and insights into its financial performance and strategic initiatives. The company reported $81.8 million in total revenue for Q2 2025, with core revenue (excluding COVID-19 testing) at $81.7 million, reflecting a 16% year-over-year increase. Gross margin on a non-GAAP basis was 44.2%, while GAAP gross margin was 42.1%. Operating expenses on a non-GAAP basis were $43.9 million, with GAAP operating expenses at $54.1 million. A GAAP loss of $19 million was recorded, impacted by a $9.9 million non-cash impairment charge. The company raised its full-year revenue guidance for 2025 to $320 million, representing a 14% year-over-year growth. Non-GAAP EPS guidance improved from a loss of $0.65 to $0.35 per share. The company also highlighted the progress in its therapeutic pipeline, with FID-007 in Phase II trials, expected to cost $30 million, and FID-022 entering Phase I trials, expected to cost $8 million. The company emphasized its strong cash position, ending the quarter with $777.5 million in cash and marketable securities.

Strong Revenue Growth

Core revenue reached $81.7 million, representing a 16% year-over-year increase and an 11% sequential increase. Precision Diagnostics was up 7%, Biopharma Services surged by 54%, and Anatomic Pathology increased by 11%.

Product and Market Expansion

Launched a new whole genome sequencing service with enhanced features. Received CE Mark for Fulgent exome and Fulgent Pipeline Manager, expanding availability in Europe. Executed over 20 new managed care agreements, adding 35 million new covered lives.

Improved Financial Outlook

Increased annual revenue guidance for 2025 from $310 million to $320 million, representing a 14% year-over-year growth.

Therapeutic Development Progress

FID-007 progressing through Phase II clinical trial with 32 patients enrolled. FID-022 Phase I trial underway, with promising potential for treating various cancers.

Fulgent Genetics (FLGT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FLGT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.22 / -	0.31	―	―	―
Aug 01, 2025	2025 (Q2)	-0.18 / 0.07	0.15	-53.33% (-0.08)
May 02, 2025	2025 (Q1)	-0.18 / 0.04	-0.01	500.00% (+0.05)	―
Feb 28, 2025	2024 (Q4)	-0.12 / 0.04	0.28	-85.71% (-0.24)	―
Nov 08, 2024	2024 (Q3)	-0.15 / 0.31	-0.39	179.49% (+0.70)
Aug 02, 2024	2024 (Q2)	-0.30 / 0.15	-0.08	287.50% (+0.23)
May 03, 2024	2024 (Q1)	-0.32 / -0.01	-0.22	95.45% (+0.21)
Feb 28, 2024	2023 (Q4)	-0.29 / 0.28	-0.48	158.33% (+0.76)
Nov 03, 2023	2023 (Q3)	-0.32 / -0.39	0.32	-221.88% (-0.71)
Aug 04, 2023	2023 (Q2)	-0.33 / -0.08	0.78	-110.26% (-0.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FLGT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 01, 2025	$17.18	$18.53	+7.86%
May 02, 2025	$17.25	$20.54	+19.07%
Feb 28, 2025	$15.69	$15.45	-1.53%
Nov 08, 2024	$22.02	$19.43	-11.76%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fulgent Genetics Inc (FLGT) report earnings?

Fulgent Genetics Inc (FLGT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Fulgent Genetics Inc (FLGT) earnings time?

Fulgent Genetics Inc (FLGT) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FLGT EPS forecast?

FLGT EPS forecast for the fiscal quarter 2025 (Q3) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing